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INTRODUCTION
The prevalence of functional dyspepsia (FD) is high throughout
the world, however few effective treatments are available (1). Ap-
proximately 10% of the population has FD in Japan (2). FD leads
to a decreased quality of life and productivity resulting in high so-
cial costs and absenteeism (3). Therefore, it is important to develop
effective treatments for this common condition. There are few arti-
cles about the effects of acotiamide on upper and lower gastrointes-
tinal (GI) symptoms despite the fact that FD frequently overlaps
with gastroesophageal reflux disease (GERD) and irritable bowel
syndrome (2).
Acotiamide, a novel GI motility modulator, was made available
in Japan in June 2013. Its main pharmacological effect is to increase
the release of the acetylcholine ligand from cholinergic nerve ter-
minals by the inhibition of acetylcholine esterase (4). It also antago-
nizes M1 and M2 muscarinic receptors that modulate acetylcholine
release (5). A recent randomized controlled study showed that
acotiamide improves impaired gastric accommodation and de-
layed gastric emptying (6). The effect of acotiamide on the brain-
gut axis was reported in a rat model and showed improvement of
delayed gastric emptying and feeding inhibition (7).
FD is divided into two categories : epigastric pain syndrome
(EPS) and postprandial distress syndrome (PDS). The effect of aco-
tiamide on PDS has been described regarding postprandial fullness,
upper abdominal bloating and early satiety following randomized
controlled studies (8, 9). However, the effect of acotiamide on EPS
has not been clarified and its effect on other GI symptoms has not
been reported. Based on the modulation of motility, acotiamide
may be effective in relieving other GI symptoms by modulating
GI motility. The aim of this study is to evaluate the effect of acotia-
mide on upper and lower GI symptoms in patients with FD.
PATIENTS AND METHODS
Eighty-eight patients with FD were treated with acotiamide
(300 mg per day) from May 2014 to September 2015. The Izumo
scale (10) (Figure 1), commonly used in clinical practice, was used
to evaluate patient quality of life. This scale was designed to detect
changes of quality of life caused by abdominal symptoms frequently
noted by Japanese patients. We retrospectively reviewed the clini-
cal findings, medical history, endoscopic findings, Helicobacter
pylori (H. pylori) infection status and Izumo scale scores for pa-
tients treated with acotiamide. Of all patients treated, 36 were
excluded from the study because they lacked three months of
follow-up. Consequently, 51 patients with FD treated with acotia-
mide were included in the final study cohort. The Institutional
Review Board approved this retrospective review.
Diagnosis of FD
FD was diagnosed according to the guidelines of the Japanese
Society of Gastroenterology (JSGE) (11) as a condition with chronic
symptoms centered in the upper abdomen, such as epigastric pain
or discomfort, in the absence of any organic, systemic, or metabolic
disease likely to explain the symptoms. According to the guide-
lines, symptom severity and degree of quality of life for six months
or more in the Roma III criteria are not different from those for less
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than one month in Japanese patients (11, 12). Therefore, we defined
the term “chronic symptoms” as symptoms continuing for more
than one month in this study. Although this criterion is different
from the Rome III criteria requiring at least a three-month duration
of symptoms, we could not apply the Rome III criteria to Japanese
patients who have access to medical care through the national
health insurance system. Generally, symptomatic people in Japan
do not wait to see a doctor for more than three months, and the
duration of symptoms when treatment is initiated is relatively short.
Kinoshita et al. reported that only 12.3% of people in Japan with
dyspepsia fulfill the Rome III criteria (12). All 53 patients under-
went esophagogastroduodenoscopy (EGD) prior to acotiamide
administration, eliminating any endoscopic findings to explain the
symptoms in all patients. Therefore, the diagnosis of FD was es-
tablished after EGD.
Criteria for improvement and resolution of symptoms
We evaluated each GI symptom using the Izumo scale (10)
(Figure 1) which includes 15 items, and has the following five do-
mains, each evaluated by three questions : GERD (Q1-3), EPS
(Q4-6), PDS (Q7-9), constipation (Q10-12) and diarrhea (Q13-
15). Domain-specific scores range from zero to 15. In this study,
four or more domain-specific scores were considered “significant
symptoms”. We assessed the Izumo scale before, then at one and
three months after starting acotiamide. Since FD comprises EPS
and PDS, we added the scores of the EPS (Q4-6, zero to 15 points)
and PDS domains (Q7-9, zero to 15 points) to evaluate the severity
of FD, with the total score ranging from zero to 30 points. Higher
scores indicate worse symptoms. We defined “improvement of
symptoms” as a score which decreased by 50% or more, “resolution
of symptoms” as a score decreased to one or zero, and “aggravation
of symptoms” as a score increased by three or more points from
the initial score.
Additional investigations
In addition to EGD, patients underwent further evaluation. Ab-
dominal ultrasound was performed in 43/51 patients (84%), and
colonoscopy was performed 11/51 patients (22%). All studies were
performed before the starting acotiamide and did not reveal pa-
thology to explain the symptoms.
Statistical analysis
Data were analyzed with StatFlex ver. 6.0 software (Artech Co.,
Ltd. Osaka, Japan). Categorical data were compared using the chi -
square test. Predictive factors for successful acotiamide treatment
were evaluated with multiple logistic regression analysis. Differences
Figure 1. The Izumo scale, designed to evaluate abdominal symptom-related quality of life impairment. (Cited from ref (10).)
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between variables with p0.05 are considered significant.
RESULTS
Baseline characteristics of patients
We retrospectively reviewed the clinical data of 51 outpatients
with FD treated with acotiamide. Demographic data for the 51
patients in the study are shown in Table 1. Symptoms of GERD
complicated the clinical presentation in more than one-half of the
patients. In about one-half of the patients, a proton pump inhibitor
was administered for at least one month prior to starting acotia-
mide, for the treatment of GERD. Acotiamide was given in addition
to the previously administered proton pump inhibitor. Three pa-
tients were treated with anti -depressants or anti -anxiety medica-
tions, which were continued after starting acotiamide therapy.
Only one patient was treated with mosapride and it was changed
to acotiamide. No additional medications for FD were prescribed
during the three-month study period. EGD showed gastric atro-
phy in two-thirds of the patients, but no gastric cancers or ulcers
were found. No adverse events occurred.
The effect of acotiamide on FD symptoms
The effect of acotiamide on patients with FD was evaluated (n=
51) (Figure 2). At one month, the rate of improvement of FD symp-
toms was 61% (31/51), and the rate of resolution of symptoms was
17% (9/51). At three months, the rate of improvement of symptoms
was increased to 80% (41/51) and the rate of resolution of symptoms
was 33% (17/51).
We next evaluated changes in EPS (n=33) and PDS (n=41) symp-
toms in patients with FD (Figure 3). EPS symptoms improved in
about 60-70% of patients taking acotiamide, and about 40% of patients
showed resolution of EPS symptoms, but there was no significant
Table 1. Characteristics of 51 patients with functional dyspepsia
Gender (male), n (%) 23 (45%)
Age (meanSD), years 55.716.3
Body Mass Index (meanSD) kg/m2 22.34.0
Alcohol use (20 g/day), n 9 (18%)
Smoking, n 8(16%)
Duration of functional dyspepsia, days, median (range) 92 (32-7680)
Comorbidities, n
Hypertension 14 (27%)
Diabetes Mellitus 2 (4%)
Hyperlipidemia 14 (27%)
Depression 3 (6%)
Functional dyspepsia symptoms, n
Epigastric pain syndrome 33 (70%)
Postprandial distress syndrome 41 (79%)
Functional dyspepsia (diagnosed by Rome III criteria), n 18 (35%)
Other gastrointestinal symptoms, n
Gastroesophageal Reflux Disease 29 (57%)
Constipation 19 (37%)
Diarrhea 12 (24%)
Prior proton pump inhibitor use, n 28 (55%)
Helicobacter pylori infection, n
Infected 15 (29%)
Not infected without eradication 31 (61%)
Not infected after eradication 5 (10%)
Endoscopic findings, n
Gastric atrophy 36 (69%)
Regurgitation esophagitis, LA grade (N/M/A/B/C/D) 30/18/1/2/0/0
Hiatal hernia 1 (2%)
Duodenal ulcerscar 1 (2%)
SD : Standard deviation, LA : Los Angeles
Figure 2. Improvement and resolution of symptoms of functional dys-
pepsia associated with acotiamide therapy.
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difference at one and three months. In contrast, there was a signifi-
cant difference in the rate of improvement and resolution of PDS
symptoms at one and three months after starting acotiamide ther-
apy (p=0.021 and p=0.004, respectively).
Comparing EPS and PDS symptoms, the rates of improvement
were almost the same at one and three months after starting aco-
tiamide therapy (Figure 3). However, the rate of resolution of EPS
symptoms was significantly higher than PDS symptoms at one
month (14/33 [42%] vs 7/41 [17%], p=0.016). At three months, the
rates were similar because of the amelioration of PDS symptoms
(13/33 [39%] vs 19/41 [46%], p=0.548). No patient reported wors-
ening of EPS or PDS symptoms in comparison with symptoms be-
fore treatment. The time to improvement in PDS symptoms took
longer than that for EPS after starting acotiamide therapy.
Predictive factors associated with the effects of acotiamide
We attempted to identify a factor which predicts the effect of aco-
tiamide on FD symptoms at three months after starting acotiamide
therapy (Table 2). We evaluated gender, age, body mass index,
alcohol habits, smoking habits, disease duration, complication of
GERD, constipation and diarrhea, H. pylori status, gastric atrophy
and severity of FD symptoms using Izumo scale scores before
treatment. Age, body mass index, disease duration and severity
of FD symptoms before treatment were evaluated as continuous
variables. Based on this analysis, the severity of FD symptoms be-
fore treatment was significantly associated with failed acotiamide
therapy (p=0.013).
Acotiamide effect on other GI symptoms
We next evaluated the effects of acotiamide on other GI symp-
toms including GERD, constipation and diarrhea (Figure 4). The
rate of improvement of GERD was higher than that for constipation
and diarrhea. None of the symptoms were aggravated at three
months after starting treatment.
DISCUSSION
The present study reviews outcomes at both one and three
months for patients with FD receiving acotiamide therapy regard-
ing symptoms including EPS, PDS, GERD, constipation and diar-
rhea. Acotiamide improved and resolved more apparently the
symptoms of FD at three months than at one month. The rates of
improvement and resolution of EPS symptoms increased at one
Figure 3. The effects of acotiamide on symptoms of epigastric pain syndrome and postprandial distress syndrome at one and three months. EPS :
epigastric pain syndrome, PDS : postprandial distress syndrome.
Table 2. Factors predictive of successful acotiamide therapy for symptoms of functional dyspepsia
Odds ratio 95% confidence interval p -value
Male gender 0.466 0.078 ～ 2.764 0.401
Age 0.977 0.918 ～ 1.040 0.476
Body mass index 0.907 0.725 ～ 1.136 0.398
Alcohol use (20 g/day) 0.334 0.018 ～ 5.895 0.454
Current smoking 0.371 0.019 ～ 7.103 0.510
Disease duration 1.000 0.999 ～ 1.000 0.258
Complication of GERD 0.823 0.614 ～ 1.103 0.192
Complication of constipation 0.794 0.547 ～ 1.151 0.223
Complication of diarrhea 1.157 0.884 ～ 1.515 0.285
Helicobacter pylori infection 2.838 0.363 ～ 22.19 0.320
Gastric atrophy 0.231 0.026 ～ 2.023 0.186
Severity of functional dyspepsia 0.678 0.498 ～ 0.923 0.013
GERD : gastroesophageal reflux disease
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month, maintained up to three months, but symptoms of PDS were
significantly improved at three months compared with one month.
At one month, the rate of resolution of symptoms of PDS in pa-
tients taking acotiamide in this study was similar to that reported
in a previous study (8). The resolution of symptoms of EPS (42%)
showed a rapid increase after starting treatment and was signifi-
cantly greater than that for symptoms of PDS (17%) and was sus-
tained at three months. Acotiamide has the potential to be the drug
of choice for patients with EPS, although a treatment algorithm
including acid suppressive therapy was suggested as the first choice
for patients with EPS (13). However, the effect of acotiamide on
EPS symptoms remained less defined in a meta-analysis (14).
Therefore, prospective studies are necessary to clarify the effect
of acotiamide on symptoms of EPS.
Acotiamide had a high rate of improvement and resolution of
symptoms of FD at three months than at one month in this study.
This trend is interesting because previous studies have focused on
short- term outcomes (6,15). The rates of improvement and reso-
lution of symptoms of EPS did not change comparing one and three
months, but PDS symptoms at three months were significantly
improved compared to results at one month. The improvement
in symptoms of PDS took longer to improve than those of EPS,
although the detailed mechanism remains unknown. Therefore,
the effect of acotiamide on EPS can be evaluated at one month after
starting treatment, but at least three months is necessary to deter-
mine the effects on symptoms of PDS.
Matsueda et al. reported that the improvement rate of global
overall treatment efficacy (OTE) showed a rapid increase at one
week, reaching 60% at eight weeks and was subsequently main-
tained. However, their data showed a gradual increase in the rate
of resolution of PDS symptoms up to eight weeks (9). Therefore,
the global OTE and PDS scores may not be related when evaluating
the rapidity with which symptoms are improved. This dissociation
may be explained by our data, showing a rapid improvement in
symptoms of EPS at one month followed by a gradual improvement
of symptoms of PDS up to three months. The rate of improvement
in symptoms of EPS may influence the overall symptom score es-
pecially early in the treatment course with acotiamide. Therefore,
it may be meaningful to add an evaluation of EPS symptoms, as
shown in our data, to an overall evaluation of FD, although the
Izumo scales used in our study are different from the OTE scores
used to assess FD symptoms.
We attempted to identify factors which predict the outcomes
with acotiamide treatment. A less favorable response with the use
of prokinetic drugs was reported in patients with a long duration
of symptoms of FD (16). In the present study, symptom duration
did not affect the efficacy of acotiamide to relieve symptoms. The
severity of symptoms of FD was a significant factor for failed reso-
lution of FD symptoms at three months. Additional treatment
should be considered for such patients.
In this study, acotiamide improved symptoms of GERD, consti-
pation and diarrhea in 30-70% of patients. The favorable trend for
relief of GERD symptoms may be explained by the improved gas-
tric emptying time as a result of acotiamide treatment. Overlap with
lower GI symptoms is well recognized in patients with symptoms
of FD, and about half of patients with FD also have lower GI symp-
toms in the present study similar to that reported in previous stud-
ies (2, 17). Since many patients have both upper GI symptoms of
FD and lower GI symptoms, it is important to elucidate the influ-
ence of FD treatment on lower GI symptoms. Acotiamide increases
release of the acetylcholine, and relief from constipation may be
partially explained by increased intestinal motility. It is difficult to
explain the reported improvement in diarrhea. FD is highly influ-
enced by stress- induced factors (7). One possible explanation is
an acotiamide effect on stress-related genes that may result in im-
provement of lower GI symptoms (7). In this study, the overlap of
FD and lower GI symptoms did not affect the effect of acotiamide on
FD symptoms (Table 2). The number of patients with diarrhea was
comparatively small in this study (n=12). Thus, caution must be
exercised when interpreting these results showing a favorable ef-
fect of acotiamide on lower GI symptoms. Placebo- like effects of
acotiamide may be partially responsible. In this study, acotiamide
was used to treat patients with FD symptoms, and not lower GI
symptoms. Therefore, we have clarified at least, that acotiamide
treatment shows a favorable trend of improvement of constipation
or diarrhea.
We recognize the limitations of this study, including that it is a
retrospective study evaluating the effect of acotiamide, given be-
fore treatment and at one and three months after. A large number
of patients in a controlled prospective study is necessary to de-
termine the efficacy of acotiamide for functional GI disorders and
their long-term outcomes.
In conclusion, acotiamide significantly improves the symptoms
of EPS as well as PDS at three months. The improvement in symp-
toms of PDS takes longer than that for EPS. Although the effect of
acotiamide on EPS can be determined at one month after beginning
Figure 4. The effect of acotiamide on symptoms of gastroesophageal reflux disease, constipation and diarrhea. GERD : gastroesophageal reflux
disease.
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treatment, at least three months is needed to determine the effect
on symptoms of PDS. A favorite trend of improvement of symptoms
exists in GERD, constipation or diarrhea. Acotiamide has the po-
tential to be a first - line therapy for patients with EPS as well as PDS.
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